This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Apr;33(4):e201-e202.

doi: 10.1016/j.clon.2020.11.003. Epub 2020 Nov 20.

Assessing New Drugs in Advanced Cancer: Beyond Randomised Evidence

D Dodwell¹, R Shakir²

Affiliations

Affiliations

¹ Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: david.dodwell@ndph.ox.ac.uk.
² Nuffield Department of Population Health, University of Oxford, Oxford, UK.

PMID: 33223383
DOI: 10.1016/j.clon.2020.11.003

Editorial

Assessing New Drugs in Advanced Cancer: Beyond Randomised Evidence

D Dodwell et al. Clin Oncol (R Coll Radiol). 2021 Apr.

. 2021 Apr;33(4):e201-e202.

doi: 10.1016/j.clon.2020.11.003. Epub 2020 Nov 20.

Authors

D Dodwell¹, R Shakir²

Affiliations

¹ Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: david.dodwell@ndph.ox.ac.uk.
² Nuffield Department of Population Health, University of Oxford, Oxford, UK.

PMID: 33223383
DOI: 10.1016/j.clon.2020.11.003

No abstract available

PubMed Disclaimer

Publication types

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations